News

• Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company
  01/12/2021 / 13:00 - GlobeNewswire
•  
• Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
  12/17/2020 / 14:00 - GlobeNewswire
•  
• Sarepta Therapeutics Announces Executive Management Changes
  12/14/2020 / 14:30 - GlobeNewswire
•  
• CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
  12/14/2020 / 14:00 - GlobeNewswire
•  
• Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
  12/10/2020 / 14:00 - GlobeNewswire
•  
• Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
  12/09/2020 / 14:02 - GlobeNewswire
•  
• CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
  12/05/2020 / 18:30 - GlobeNewswire
•  
• CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia
  12/01/2020 / 15:00 - GlobeNewswire
•  
• Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
  12/01/2020 / 13:00 - GlobeNewswire
•  
• CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
  11/24/2020 / 14:00 - GlobeNewswire
•  
• Cytokinetics Names Nancy Wysenski to Board of Directors
  11/20/2020 / 13:30 - GlobeNewswire
•  
• Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
  11/17/2020 / 13:00 - GlobeNewswire
•  
• Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020
  11/16/2020 / 22:05 - GlobeNewswire
•  
• Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer
  11/12/2020 / 15:00 - GlobeNewswire
•  
• Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
  11/05/2020 / 13:00 - GlobeNewswire